We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

66 hedge funds and large institutions have $81.2M invested in LENZ Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

11% more capital invested

Capital invested by funds: $72.9M → $81.2M (+$8.38M)

6% more funds holding

Funds holding: 62 → 66 (+4)

0.38% more ownership

Funds ownership: 7.31% → 7.68% (+0.38%)

0% more call options, than puts

Call options by funds: $1.53M | Put options by funds: $1.53M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
66
Holders Change
+4
Holders Change %
+6.45%
% of All Funds
1.04%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
22
Reduced
14
Closed
11
Calls
$1.53M
Puts
$1.53M
Net Calls
+$3K
Net Calls Change
+$18K

Top Buyers

1
BlackRock
BlackRock
New York
+$3.43M
2
PM
Prosight Management
Texas
+$2.35M
3
State Street
State Street
Massachusetts
+$1M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$773K
5
CA
CHI Advisors
New York
+$659K

Top Sellers

1
KPF
K2 Principal Fund
Ontario, Canada
-$2.38M
2
LCM
Laurion Capital Management
New York
-$1.4M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$1.11M
4
WSL
Western Standard LLC
California
-$914K
5
Morgan Stanley
Morgan Stanley
New York
-$378K
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$22.2M – – –
SB
2
Samsara BioCapital
California
$22M – – –
TCM
3
Tang Capital Management
California
$5.42M +$163K +8,165 +3%
BlackRock
4
BlackRock
New York
$4.45M +$3.43M +171,851 +237%
PM
5
Prosight Management
Texas
$4.42M +$2.35M +117,619 +94%
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.59M +$414K +20,744 +12%
Citadel Advisors
7
Citadel Advisors
Florida
$3.13M +$94.5K +4,731 +3%
BOTOTLSJU
8
Board of Trustees of The Leland Stanford Junior University
California
$1.83M – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.35M +$773K +38,684 +109%
State Street
10
State Street
Massachusetts
$1.15M +$1M +50,259 +395%
Federated Hermes
11
Federated Hermes
Pennsylvania
$1.06M -$5.16K -258 -0.4%
OMC
12
OUP Management Company
Pennsylvania
$1.06M – – –
PFMU
13
Privium Fund Management (UK)
United Kingdom
$694K -$54K -2,701 -7%
Northern Trust
14
Northern Trust
Illinois
$652K +$507K +25,392 +243%
Renaissance Technologies
15
Renaissance Technologies
New York
$635K +$45.4K +2,271 +7%
CA
16
CHI Advisors
New York
$600K +$659K +32,991 New
Verition Fund Management
17
Verition Fund Management
Connecticut
$596K -$1.11M -55,654 -63%
CAM
18
Cormorant Asset Management
Massachusetts
$519K – – –
AI
19
Acuitas Investments
Washington
$509K +$559K +27,967 New
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$484K +$531K +26,578 New
WSL
21
Western Standard LLC
California
$455K -$914K -45,758 -65%
Two Sigma Investments
22
Two Sigma Investments
New York
$437K +$69.4K +3,473 +17%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$414K -$142K -7,086 -24%
BCM
24
BML Capital Management
Indiana
$396K – – –
BCM
25
Bridgeway Capital Management
Texas
$339K -$4.16K -208 -1%
1
2 3

LENZ Hedge Fund Activity: Q2 2023 in Review

66 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2023, worth a combined $81.2M — up 11% from $72.9M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new LENZ positions and 11 closed out — a net gain of 4 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $3.43M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $2.38M sold.

  • 66 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2023, up from 62 in Q1 2023.
  • Funds reported $81.2M of LENZ Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
  • 15 funds opened new LENZ Therapeutics positions in Q2 2023 and 11 closed out, a net change of +4 holders.
  • The largest LENZ Therapeutics buyer in Q2 2023 was BlackRock, an estimated $3.43M added.
  • The largest LENZ Therapeutics seller in Q2 2023 was K2 Principal Fund, an estimated $2.38M sold.

Based on aggregated 13F filings for Q2 2023.